Health Law Experts: AI Regulation in Healthcare Remains ‘Still Complicated’ Despite New FDA Guidance

A recent health law commentary describes the state of AI regulation in healthcare as highly complex, noting that the FDA continues to prioritize premarket review for higher-risk AI systems such as radiology and ECG interpreters. The piece explains that the January 2026 clinical decision support guidance clarifies when AI tools directly influencing clinical judgment will be treated as regulated medical devices, reinforcing the need for robust validation and oversight.